Article
Dr. McKay on Evaluating Radium-223 in HRD-Mutant mCRPC
Author(s):
Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses planned research in which investigators will evaluate the use of radium-223 dichloride (Xofigo) in patients with homologous recombination deficiency (HRD)-mutant metastatic castration-resistant prostate cancer (mCRPC).
Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses planned research in which investigators will evaluate the use of radium-223 dichloride (Xofigo) in patients with homologous recombination deficiency (HRD)-mutant metastatic castration-resistant prostate cancer (mCRPC).
There has been a lot of excitement regarding the DNA repair pathway in prostate cancer, says McKay. Since radium-223 is a liquid radiopharmaceutical, specifically an alpha particle that induces DNA damage in cells within the bone, it could lead to synergistic activity in patients with HRD.
As such, investigators will evaluate real-world data sets with the agent specifically in patients with HRD-mutated versus HRD-nonmutated prostate cancer, concludes McKay.
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
